Pilot Study of Physostigmine-Enhanced Opioid Analgesia

PHASE3CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Postoperative Pain
Interventions
DRUG

Physostigmine

continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --\> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours

DRUG

Placebo

"continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours~PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg"

Trial Locations (1)

8036

Hospital of the Medical University of Graz, Graz

All Listed Sponsors
lead

Medical University of Graz

OTHER

NCT01394445 - Pilot Study of Physostigmine-Enhanced Opioid Analgesia | Biotech Hunter | Biotech Hunter